Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 10 September 2008, doi:10.1136/bmj.a1580
Cite this as: BMJ 2008;337:a1580
| The first 150 words of the full text of this article appear below. |
We found that dissent to storage and use of samples by Swedish healthcare biobanks is rare and does not pose a threat to research, concluding that the results give prima facie reason to consider a move to an opt-out system.1
Laurie presented two controversies as evidence that opt-out systems are inappropriate.2 However, despite the controversy surrounding the Icelandic health sector database, public support continues.3 Furthermore, negative attitudes may in part arise from commercial interests,3 which are largely absent in the Swedish context. The second example was organ donation in England, which should not be confused with biobank research.
Laurie also claims that an opt-out system will be more costly because patients would have to be given "adequate information about who might have access to their samples or information, and for what purposes." We have argued elsewhere that general consent is quite sufficient, and several surveys of donors attitudes agree.4 Donors
Linus Johnsson, student1, Mats G Hansson, professor1, Stefan Eriksson, senior researcher1, Gert Helgesson, senior researcher2
1 Centre for Research Ethics and Bioethics, Uppsala University, Uppsala Science Park, SE-751 85 Uppsala, Sweden, 2 Unit for Bioethics, LIME, Karolinska Institutet, Berzelius väg 3, SE-171 77 Stockholm
linus.johnsson@crb.uu.se